EyePoint Pharmaceuticals Aiming to Enhance Lives of Patients with Serious Eye Disorders EyePoint Pharmaceuticals, Inc. is a United States-based pharmaceutical company dedicated to developing and commercializing therapeutics aimed at improving the lives of patients suffering from serious eye disorders. The company's operations extend to China and the United Kingdom as well. Its portfolio of commercial products currently includes YUTIQ, which treats chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, which targets postoperative inflammation. Leveraging its Durasert technology for sustained intraocular drug delivery, EyePoint Pharmaceuticals has developed an investigational sustained delivery intravitreal treatment called EYP-1901, which is currently in Phase 2 clinical trials. Founded in 1987, EyePoint Pharmaceuticals was previously known as pSivida Corp. and rebranded in March 2018. The company is headquartered in Watertown, Massachusetts.
EyePoint Pharmaceuticals's ticker is EYPT
The company's shares trade on the NASDAQ stock exchange
They are based in Watertown, Massachusetts
There are 51-200 employees working at EyePoint Pharmaceuticals
It is eyepointpharma.com/about
EyePoint Pharmaceuticals is in the Healthcare sector
EyePoint Pharmaceuticals is in the Biotechnology industry
The following five companies are EyePoint Pharmaceuticals's industry peers: